Xu Sui-Yi, Li Hui-Juan, Huang Jing, Li Xiu-Ping, Li Chang-Xin
Department of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi Province, People's Republic of China.
J Pain Res. 2021 Apr 20;14:1119-1127. doi: 10.2147/JPR.S305483. eCollection 2021.
Migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraine, and women are more affected than men. The aura symptoms are diverse; however, when MBA is combined with DOC, the clinical manifestations are more complicated. Coma is the most common clinical manifestation. The overall duration of the patient's DOC is short and can often return to normal within half an hour. Headache often occurs after regaining consciousness and can also occur at the same time as DOC. The most common headache is located at the occipital region. Although DOC is reversible, considering the current small number of cases, we still need to improve our understanding of the disease to avoid misdiagnosis. The MBA patient's electroencephalogram and cerebral blood flow perfusion may have transient changes and may return to normal in the interictal period or after the DOC. Although triptans have traditionally been contraindicated in MBA under drug instructions, the evidence of basilar artery constriction, as postulated in MBA, is lacking. Lasmiditan is currently the first and only 5-HT 1F receptor agonist approved by the Food and Drug Administration. The calcitonin gene-related peptide receptor antagonists and monoclonal antibody therapies may be the most promising for future consideration. Here, the pathophysiology, clinical manifestations, diagnostic tools, and treatment progress for MBA with DOC are reviewed.
伴脑干先兆偏头痛(MBA)合并意识障碍(DOC)是偏头痛的一种罕见亚型。MBA合并DOC的病理生理学尚未阐明。部分患者有偏头痛家族史,女性比男性更易患病。先兆症状多样;然而,当MBA合并DOC时,临床表现更为复杂。昏迷是最常见的临床表现。患者DOC的总体持续时间较短,通常半小时内可恢复正常。头痛常于意识恢复后出现,也可与DOC同时发生。最常见的头痛部位在枕部。尽管DOC是可逆的,但鉴于目前病例数较少,我们仍需加深对该病的认识以避免误诊。MBA患者的脑电图和脑血流灌注可能有短暂变化,在发作间期或DOC后可能恢复正常。尽管在药品说明书中,曲坦类药物传统上在MBA中被列为禁忌,但缺乏MBA中所假设的基底动脉收缩的证据。拉米地坦是目前美国食品药品监督管理局批准的首个也是唯一的5-HT 1F受体激动剂。降钙素基因相关肽受体拮抗剂和单克隆抗体疗法可能是未来最有前景的治疗方法。在此,对MBA合并DOC的病理生理学、临床表现、诊断工具和治疗进展进行综述。